Most hepatocellular carcinoma (HCC) 
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide (Zhou et al. 2016) . Even though advanced early surveillance technology has improved the life of patients diagnosed at an early stage, most patients are diagnosed with late stage of HCC. Furthermore, HCC patients do not show improved long-term disease-free survival or overall survival after surgical resection and auxiliary medication treatment. (Ye et al. 2003; Kamiyama et al. 2009; Eggert et al. 2013; Llovet et al. 2015) . One of the main reasons may lie in the complexity of the genetic background of HCC (Llovet et al. 2015) .
Fortunately, recent advances in high throughput sequencing technology have helped provide deeper insights into the genomic and transcriptome landscape of cancer.
Using genomic sequencing, researchers have identified large numbers of point mutations, insertions, and deletions as well as chromosome rearrangements in different types of cancers (Gerlinger et al. 2012; Miao et al. 2014; Shibata and Aburatani 2014; Xue et al. 2016) . RNA-Seq has become another powerful tool to explore the functional role of these genomic alterations.
Previous studies have demonstrated that fusion genes play an important role in tumorigenesis and cancer progression (Mitelman et al. 2007; Soda et al. 2007 ) and represent one of the most promising therapeutic targets in human malignancy (Rutkowski et al. 2010; Cortes et al. 2012; Kazandjian et al. 2014; Shaw et al. 2014 ).
The first fusion gene, Philadelphia chromosome, was discovered in 1960 and was approved as the therapeutic biomarker of chronic myeloid leukemia in 2001 (Nowell 1960; Topaly et al. 2001; Cohen et al. 2002) . According to the FusionCancer and Mitelman Database, nearly 10,000 fusion genes have since been detected . In addition, several highly recurrent fusion genes in specific tumor types have been well characterized. For example, Soda et al. showed that nearly 6.7% of non-small-cell lung cancer (NSCLC) patients carry the EML4-ALK fusion (Soda et al. 2007 ). Approximately 55 % of prostate cancer show the presence of ERG fusion (Hessels and Schalken 2013) . The DNAJB1-PRKACA fusion was found in 100% of fibrolamellar HCC (FL-HCC) (15/15) (Honeyman et al. 2014 ).
The identity of fusion genes and the recurrent fusion events in HCC have not been comprehensively investigated. A previous study re-analyzed RNA-Seq data of normal liver tissue and HepG2 cells from the National Center for Biotechnology Information Sequence Read Archive database and identified 46 fusion genes (Lin et al. 2014a ). Another study only detected five fusion genes from 11 HCC tissues and 11 paired portal vein tumor thrombus tissues . Owing to the limited numbers of samples and different analysis strategies, the studies did not identify recurrent fusion genes.
Here we used RNA-seq data of multiple lesions of two HCC patients to explore gene fusions in HCC and validate potential fusions using publicly available RNA-seq datasets of HCC. Our efforts unveiled several novel and recurrent fusions in HCC, suggesting their potential as diagnostic markers or molecular therapeutic targets.
Results
To gain insight into fusion events in HCC, we performed paired-end RNA sequencing on multiple lesions of two Chinese HCC patients (PI and PII), including adjacent noncancerous liver (PI-N), primary HCC (PI-P), intrahepatic metastases (PI-M), and portal vein tumor thrombus (PI-V) from Patient I, and noncancerous liver (PII-N) and two distant HCCs located in the left (PII-L) and right lobes (PII-R) from Patient II. We obtained ~7,152 million reads (Supplementary Table 1) , which is sufficient for transcriptome analysis. We used STAR software (Dobin et al. 2013) to align reads to the hg19 reference genome. An average of approximately 86 million reads per sample was uniquely mapped to the reference genome (Supplementary Table 1 ). Combing all seven liver samples, we detected about 19,000 annotated genes with a read count more than 10 in at least two samples. We found that 80% (15, 302) of expressed genes were protein-coding genes. Interestingly, we also found that 14% (2,651) of expressed genes were long noncoding RNAs (lncRNAs) and 5% were pseudogenes annotated in GENCODE (Supplementary Figure 1A) .
To further explore the differences of the transcriptome in the two patients, we merged all samples and found no obvious differences between the transcriptomes. However, in both patients, the HCC tumor samples expressed more genes compared with adjacent noncancerous liver samples, suggesting that HCC tumor samples presented a more complex transcriptome (Supplementary Figure 1B and C) . In addition, we found more lncRNAs expressed in the HCC tumor samples in both patients than adjacent noncancerous liver samples, indicating that lncRNAs may play key roles in the tumorigenesis of HCC (Supplementary Figure 1B and C) .
Landscape of fusion events in HCC
Transcriptome analysis has been widely used to identify gene fusions in human cancers (Bao et al. 2014; Stransky et al. 2014; Yoshihara et al. 2015) . We used paired-end reads whose two segments mapped to distinct genes to determine gene fusions by STAR using the parameters suggested by Nicolas et al. (Stransky et al. 2014 ) A total of 2,354 different gene fusions with junction read count more than 3 (Supplementary Figure 2A) was identified in the total combined samples. HCC samples possessed more fusion events and involved fusion genes than adjacent normal tissues ( Figure 1A) . Furthermore, the number of gene fusions gradually increased across the PI_N, PI_P, PI_V and PI_M samples ( Figure 1A ), which is consistent with intrahepatic metastasis process. Additionally, PI_M showed the most gene fusion events and most involved fusion genes (Supplementary Figure 2B) . The right lesion of patient PII showed 241 fusion events, which is more than 193 of left lesion. By analyzing the genome position of fusion genes, we found that more than 85% fusion events were between two different chromosomes ( Figure 1B ). We next classified fusion events into eight types according to GENCODE: protein-protein, lncRNA-lncRNA, protein-lncRNA, lncRNA-protein, pseudogene-protein, proteinpseudogene, pseudogene-pseudogene and others. As expected, most fusion events (on average, 85%) were between protein-coding genes in all samples ( Figure 1C ). The number of fusion types in adjacent normal tissues was less than those in HCC samples, suggesting that more complex fusions were involved in HCC. Moreover, the proportions of distinct fusion types were different across all samples ( Figure 1C) , and the proportion of protein-ncRNA fusion events in PI was higher than PII. Through comparing the fusion types of protein-protein and lncRNA fusions between PI and PII, we found that the overlap were both small indicating large differences of fusion landscape between two patients. Interestingly, we found that a few genes can fuse to more than one partner genes (Supplementary figure 3) . For example, NDRG1 was a suppressor gene, but it occurred in CCNK--NDRG1 and NDRG1--DUSP3 fusions in PI-V. In summary, there were many fusion events in Hepatocellular carcinoma. Especially there were some fusions involved in ncRNAs (such as lncRNAs and pseudogenes) highlighting the importance of ncRNAs in the development of HCC.
Recurrent fusion events in HCC
Recurrent fusion events contribute to the development of human cancers and serve as biomarkers or therapy targets of some cancers (Elefanty et al. 1990; Bao et al. 2014; Dhanasekaran et al. 2014) . We next examined potential recurrent gene fusions contributing to the pathogenesis of HCC. By combining all gene fusions, we found that majority of gene fusions only occurred in individual samples (Supplementary Figure 4A) , and only a few recurrent fusions were present in more than two samples.
Of 2,354 fusions, we identified 20 (0.9%) recurrent fusions appearing in more than two samples. As shown in Figure 2A , the recurrent fusions could well classify all samples into two patients. Moreover, except for a few recurrent cases, most fusion genes appeared only once in the seven samples ( Figure 2C ). To further explore the functional difference of gene fusions across HCC samples and adjacent normal tissues, we performed functional enrichment analysis using all genes involved in fusion events in each sample. The genes were commonly enriched in several biological processes, such as lipid metabolic process and oxidation-reduction process ( Figure 2A and B, Supplementary Figure 4B ). HCC samples of PI were enriched in the same biological process, such as cell cycle and apoptotic process. Notably, the majority of enriched functions were only enriched in one sample, suggesting that each sample generated fusion events with specific consequences. For example, fusion genes in PI-P were involved in cancer-related functions and pathways, such as gland development, JNK cascade and p53 signaling pathway. However, fusion genes in PI-M were enriched in migration-related functions, such as cell migration function and focal adhesion pathway. Similarly, the enriched functions of fusion genes in patient PII were also different. Fusion genes in PI-R were involved in Notch signaling pathway regulation ( Figure 2B and Supplementary Figure   4B ).
Owing to our small sample size, our initial findings may exclude some important recurrent fusions in HCC. Therefore, we collected public available RNA-seq data of HCC to identify reliable recurrent fusions. We obtained four RNA-seq datasets (accession number: GSE65485 , GSE55758 (Gao et al. 2015) , GSE33294 ) and SRP007560 (Lin et al. 2014b );
Supplementary Table 2) involved 79 public HCC samples using keywords of "hepatocellular carcinoma", "HCC", "liver", "RNA-seq", "next generation sequencing", and "high through output" in GEO database and NCBI SRA database.
To obtain recurrent fusions, we selected 2,354 fusion events with at least three junction reads. In the public datasets, we obtained 24,960 fusion events in total, including 23,795 fusions in GSE65485, 1,132 fusions in GSE55758, 40 fusions in GSE33294, and 92 fusions in SRP007560. We obtained 43 gene fusions that occurred in at least two samples in our HCC samples, or presented in one sample in our data and also occurred in at least one sample in the 79 public samples. The remaining 2,311 gene fusions occurred just once in our seven samples, with no events detected in the public data ( 
Identification of candidate fusion events associated with HCC
We used four known fusion databases including ChimerDB, FusionCancer,
Mitelman and MCL to examine if the identified fusion events were associated with human diseases. In addition, we gathered five sets of tumor-associated fusion events derived from recently published literatures (Stransky et al. 2014) , (Bao et al. 2014 ), (Dhanasekaran et al. 2014) , (Sia et al. 2015) , (Torres-Garcia et al. 2014) . We C15orf57-CBX3 were 2, 2.6 and 5, respectively. We selected 17 fusions with ratios more than 2, and 9 fusions that occurred in only cancer samples as candidate fusion events. For example, the fusion C15orf57-CBX3 occurred in PII-L and PII-R.
C15orf57-CBX3 was also present in 22.7% (18) in the second exon of C15orf57 was located in the CCDC32 conserved domain (pfam14989), suggesting that the domain may be truncated and the protein structure was affected by the fusion. The breakpoint in the first exon of CBX3 (chr7:26241389) is located upstream of the CHROMO and ChSh conserved domains without destroying the domain ( Figure 3A and Supplementary Figure 5A) . Therefore, the Another fusion, AP3D1-SLC6A8, which occurred in PI-N, PI-P and PI-V with abundant of junction reads, was also present in nine public HCC samples without any supporting normal public liver sample. AP3D1-SLC6A8 showed the highest ratio of disease sample (11 HCC samples vs. 1 adjacent noncancerous liver PI-N, Supplementary Table 4 ). The AP3D1 gene encodes a protein subunit of the AP3 adaptor-like complex, which is associated with the golgi region, as well as more peripheral structures, suggesting an important role in the translation process (Petrenko et al. 2006) . The SLC6A8 gene encodes a plasma membrane protein that transports creatine into and out of cells and is also involved in the ion transport process.
Furthermore, we found that the breakpoint (chr19:2101455) in the 3′ UTR of AP3D1 and does not affect protein domains. The breakpoint (chrX: 152961595) of SLC6A8 was also located in the 3′ UTR ( Figure 3B and Supplementary Figure 5B) . Therefore, the AP3D1-SLC6A8 fusion retains full-length AP3D1 and part of 3′ UTR region of SLC6A8. The fused 3′ UTR of SLC6A8 may influence the regulation of AP3D1.
Moreover, AP3D1 was reported to be fused with the NSUN2 gene in HCC in the FusionCancer database. In addition, AP3D1 was reported to be involved in fusions in cervical cancer, lung cancer and colon cancer in the FusionCancer database, indicating that AP3D1 may be widely involved in fusions in human cancer. SLC6A8
was annotated to participate in melanoma (SLC6A10P-SLC6A8) and glioblastomas (SLC6A8-GABRA3) in FusionCancer. Thus, the AP3D1-SLC6A8 fusion may be associated with tumorigenesis of HCC and should be further examined.
Novel fusion events associated with HCC
In addition to recurrent gene fusions involving known fusion genes or fusion events, we found 19 novel and recurrent fusions that have not been previously annotated to diseases (Supplementary Table 7 ). For instance, the recurrent fusion DCUN1D3-GSG1L occurred in PI-P, PI-V and PI-M without any public sample support. Overexpressing DCUN1D3 gene may promote mesenchymal to epithelial-like changes and inhibit colony formation in soft agar (Huang et al. 2014 ).
GSG1L is a component of the inner core of the AMPAR complex, which modifies AMPA receptor gating. Furthermore, both fusion genes harbored the exact same breakpoint in three HCC samples ( Figure 4A and Supplementary Table 5 Table 7 ). The primer sequences are listed in Supplementary Table 8 Figure 5G ). We suspect that these clinical patients have had a history of hepatitis B virus infection for several years, and have taken place in liver cirrhosis, which is not fully normal liver tissue. In the process of liver cirrhosis, the genome of liver tissue changes dramatically, resulting in fusion events.
Kinase gene fusion in HCC
Kinase gene fusion plays an important role in tumorigenesis and targeted therapy.
However, few recurrent kinase fusion events have been reported. To examine kinase gene fusion in HCC, we selected fusion events with at least one participating kinase gene. Interestingly, unlike the previous study of Stransky et a l., we found many kinase genes in fusion events in both HCC and adjacent non-tumor tissues ( Figure 6 ). For example, MAP3K11 fusion was detected in 23.5% (4/17) of adjacent non-tumor tissues. Both BRD4 and NRBP2 were detected in 25.8% (16/62) of HCC tissues.
MET fusion was only detected in 4.8% (3/62) and 5.9% (1/17) of HCC tissues and adjacent non-tumor tissues, respectively. 
Discussion
Here, we characterized the landscape of fusions in HCC and identified 43 fusion events and confirmed 26 by RT-PCR and Sanger sequencing. Detection and characterization of fusion genes has been critical in understanding tumorigenesis, anticancer drug screening, and clinical application (Hessels and Schalken 2013; Stransky et al. 2014; Mertens et al. 2015; Yoshihara et al. 2015) . However, few fusion events are demonstrated recurrent events. Fortunately, with the development of high throughput sequencing technology as well as bioinforma tics algorithms, huge amount of fusion events has been detected (Kim and Salzberg 2011; Li et al. 2013 ).We detected a total of 2,354 candidate fusion events and only 1.8% (43/2354) of these events were recurrent. Similarly, Yoshihara et al. (Yoshihara et al. 2015) and Stransky et al. (Stransky et al. 2014 ) reported large numbers of kinase gene fusions in 13 and 20 types of cancer, respectively. However, only 7.4% and 12% were recurrent events.
Several previous studies have focused on fusion events involving protein kinase genes (Stransky et al. 2014; Yoshihara et al. 2015) because of their critical functions in cellular processes and potential targets for anti-cancer drugs. In our analysis, we did not detect protein kinase genes involved in fusion events. This difference may result from the cut-off value in the detecting process. However, some of the identified fusion proteins in our study may have important functionality in HCC. For example, C15orf57-CBX3, a recurrent fusion in 22.7% public HCC samples and 4 normal liver samples, was also a fusion protein in glioblastomas (Bao et al. 2014) and is also annotated to associate with cervical cancer, melanoma and Burkitt lymphoma in the FusionCancer database . Other fusion proteins, such as AP3D1-SLC6A8, DCUN1D3-GSG1L, and SERPINA5-SERPINA9, may also play an important role in HCC. Further studies should focus on the function of these recurrent fusion proteins.
Noncoding genes also play an important role in human disorders as well as cancer (Guarnerio et al. 2016; Xu et al. 2016) . However, to our best knowledge, up until now, few studies have focus on noncoding gene fusion events. Lau et al. reported that HBx-LINE fusion, which functions as an lncRNA, affects β-catenin transitivity and is involved in liver cancer development and progression (Lau et al. 2014 ). Dong et al. found that HCC patients carrying the HBV-MLL4 fusion have a distinct gene expression profile . In our analysis, we identified many fusion events involving noncoding genes. Notably, a higher percentage of noncoding gene fusion events were detected in the advanced HCC patient. This supports the idea that noncoding gene fusions play key roles in the progression of cancer.
We also detected many recurrent fusion events in adjacent normal tissue. For example, 27.9% (12/43) of fusion events were detected in only adjacent normal tissues and 30.2% (13/43) recurrent fusion events were observed in both HCC and adjacent normal tissues. Some were highly detected in adjacent normal tissue compared with the paired HCC tissue. Similarly, the TEL-AML1 fusion gene was reported to occur 100 times more frequently in normal individuals than leukemia patients and contributes to initiation of childhood ALL (Mori et al. 2002; Zelent et al. 2004 ). Thus, fusion events in adjacent normal tissue may serve as biomarkers of hepatitis disease progression into HCC and should be pursued in future experimental study. Successful applied drugs target on BCR-ABL1 fusion in hematological malignancy ALK fusion in NSCLC dramatically ignite the enthusiasm of deep exploration the landscape of gene fusions (Mertens et al. 2015) . Moreover, several drugs, such as imatinib and crizotinib, have been approved for targeting gene fusions in human malignant diseases. These success stories support the notion that fusion events represent promising anticancer targets. Our present result provides insight into the landscape of gene fusions in HCC and might pave the way for anti-HCC therapy. The cDNA libraries were constructed using previous studies (Miao et al. 2014) and sequenced using Illumina HiSeq™ 2000. Finally, 90*2 bp paired-end reads were obtained for each sample. The raw RNA-seq data were deposited at the European Genome-phenome Archive with accession number EGAS00001000372.
Materials and Methods

Patients and clinical samples
Gene annotations
The reference genome sequence was downloaded fro m the UCSC database (version hg19, http://genome.ucsc.edu/). The annotation of genes was downloaded from the GENCODE database (http://www.gencodegenes.org/). To identify fusions, we select the v19 version, which includes a comprehensive list of protein-coding genes and lncRNAs. A total of 57,820 genes were obtained, including 20,345
protein-coding genes, 20,345 pseudogenes and 13,870 lncRNAs.
Analysis of transcriptome data
For raw RNA-seq data, we first assessed the quality of sequencing reads by Fastqc software and then discarded low quality reads with a quality score less than 20 using the trimmomatic tool. Next, for each sample, we aligned the cleaning read to the hg19 reference genome using STAR v2.4.1, which is an ultrafast RNA-seq aligner.
For each read, no more than two mismatches were allowed in the alignment process.
Reads that were mapped to distinct genes in the reference genome were output into the chimeric-reads file and used for detection of fusion genes.
HT-seq was used for calculated read count for each gene annotated in the EMSEMBL database.
Identification of fusion genes
We used STAR-Fusion integrated in STAR software to identify potential fusion genes. Reads deposited in the chimeric-reads file indicated putative fusions.
STAR-Fusion used reads that aligned to distinct genes to detect candidate fusion genes. To reduce the number of false positive fusion genes, the length of one read aligned to distinct genes was not less than 15bp. Putative fusions between homologous genes were also discarded. Furthermore, we remained fusions with at least three junction reads, which provides direct evidence about a fusion. We also removed the fusions between mitochondria and autosome.
Functional enrichment analysis
The significance of enrichment analysis of differentially expressed protein-coding genes (DEGs) with GO terms and pathways was determined using a hypergeometric test with FDR correction (FDR ≤ 0.05). In addition, DEGs overlapped at least two genes with the enriched GO terms and pathways. The relative expression levels of the fusion genes were calculated using 2 -ΔΔCT values.
The fusion gene-specific primers and the primers for GAPDH are listed in Supplementary Table 8. 
